GlassScriptPhysician profile
Callie M Taffe
NPI 1346238722
$1,370.04
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,370.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $335.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $163.38 | 2019 | |
| Amgen INC. | $127.21 | 2019 | |
| Novo Nordisk INC | $103.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.62 | 2019 | |
| Therapeuticsmd, INC. | $64.48 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.07 | 2019 | |
| Merck Sharp & Dohme LLC | $58.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $45.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.40 | 2019 | |
| Avanir Pharmaceuticals, INC. | $33.35 | 2019 | |
| Genentech USA, INC. | $24.94 | 2019 | |
| Sanofi Pasteur INC. | $24.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.25 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $19.69 | 2019 | |
| Valeritas, INC. | $17.96 | 2019 | |
| Glaxosmithkline, LLC. | $16.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Callie Taffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.